NASDAQ:VRAY

ViewRay - VRAY Stock Forecast, Price & News

$3.79

-0.03 (-0.79%)

(As of 08/16/2022 12:00 AM ET)

Add

Compare

Today's Range: $3.70
▼
$3.84
50-Day Range: $2.60
▼
$3.82
52-Week Range: $2.39
▼
$8.25

Volume: 715,598 shs
Average Volume: 1.42 million shs
Market Capitalization: $686.03 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

ViewRay MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 84.7% Upside
$7.00 Price Target
Short Interest: Bearish
5.82% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.57
Upright™ Environmental Score
News Sentiment: -0.01
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$47,680 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.57) to ($0.50) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

368th out of 1,124 stocks

Electromedical Equipment Industry

7th out of 24 stocks

3.5

Analyst's Opinion

Consensus Rating
ViewRay has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.00, ViewRay has a forecasted upside of 84.7% from its current price of $3.79.
Amount of Analyst Coverage
ViewRay has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.82% of the float of ViewRay has been sold short.
Short Interest Ratio / Days to Cover
ViewRay has a short interest ratio ("days to cover") of 6.8.
Change versus previous month
Short interest in ViewRay has recently decreased by 0.56%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
ViewRay does not currently pay a dividend.
Dividend Growth
ViewRay does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
ViewRay has received a 76.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "MRI machines", "Radiation therapy machines", and "Medical technology engineering" products. See details.
Environmental Sustainability
The Environmental Impact score for ViewRay is -0.57.

1.7

News and Social Media Coverage

News Sentiment
ViewRay has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for ViewRay this week, compared to 2 articles on an average week.
Search Interest
3 people have searched for VRAY on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added ViewRay to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ViewRay insiders have bought more of their company's stock than they have sold. Specifically, they have bought $47,680.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 2.50% of the stock of ViewRay is held by insiders.
Percentage Held by Institutions
86.04% of the stock of ViewRay is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for ViewRay are expected to grow in the coming year, from ($0.57) to ($0.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ViewRay is -6.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ViewRay is -6.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ViewRay has a P/B Ratio of 3.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ViewRay (NASDAQ:VRAY) Stock

ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Analyst Ratings Changes

VRAY has been the subject of several recent research reports. BTIG Research lowered their price target on ViewRay from $9.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, June 24th. Piper Sandler lowered their price target on ViewRay from $7.00 to $6.00 and set an "overweight" rating for the company in a research note on Wednesday, August 3rd. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat, ViewRay currently has a consensus rating of "Moderate Buy" and a consensus target price of $7.00.

ViewRay Stock Performance

Shares of ViewRay stock opened at $3.82 on Tuesday. The company has a quick ratio of 2.66, a current ratio of 3.04 and a debt-to-equity ratio of 0.47. The stock has a 50 day moving average price of $2.96 and a two-hundred day moving average price of $3.35. ViewRay has a 12-month low of $2.39 and a 12-month high of $8.25.

Insiders Place Their Bets

In related news, Director Brian K. Roberts bought 16,000 shares of the firm's stock in a transaction on Wednesday, May 18th. The stock was purchased at an average price of $2.98 per share, with a total value of $47,680.00. Following the completion of the transaction, the director now directly owns 147,761 shares of the company's stock, valued at $440,327.78. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 2.50% of the company's stock.

Receive VRAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter.

VRAY Stock News Headlines

August 11, 2022 | finance.yahoo.com

National Cancer Center Hospital in Tokyo Upgrades to MRIdian® Linac for MRI-Guided Radiation Therapy and has treated its first patients

August 7, 2022 | americanbankingnews.com

Q4 2022 EPS Estimates for ViewRay, Inc. Reduced by Oppenheimer (NASDAQ:VRAY)

August 7, 2022 | americanbankingnews.com

Jefferies Financial Group Weighs in on ViewRay, Inc.'s Q3 2022 Earnings (NASDAQ:VRAY)

August 6, 2022 | americanbankingnews.com

Piper Sandler Cuts ViewRay (NASDAQ:VRAY) Price Target to $6.00

August 3, 2022 | benzinga.com

Where ViewRay Stands With Analysts - Benzinga

August 3, 2022 | in.investing.com

ViewRay Reports In-Line Q2 EPS; Offers FY22 Revenue Guidance By Investing.com - Investing.com India

August 3, 2022 | bizjournals.com

Medical tech company ViewRay to move headquarters to Denver - Denver Business Journal - The Business Journals

August 3, 2022 | fool.com

ViewRay, Inc. (VRAY) Q2 2022 Earnings Call Transcript - The Motley Fool

August 3, 2022 | finance.yahoo.com

ViewRay, Inc. (VRAY) Q2 2022 Earnings Call Transcript

August 3, 2022 | investing.com

ViewRay Reports In-Line Q2 EPS; Offers FY22 Revenue Guidance By Investing.com - Investing.com

August 2, 2022 | benzinga.com

ViewRay: Q2 Earnings Insights - Benzinga

August 1, 2022 | benzinga.com

Earnings Preview For ViewRay - Benzinga

July 29, 2022 | finance.yahoo.com

Centre Oscar Lambret Selects ViewRay's MRIdian® MRI-Guided Radiation Therapy System

July 19, 2022 | finance.yahoo.com

Saitama Medical University International Medical Center Selects MRIdian® MRI-Guided Radiation Therapy System

June 24, 2022 | benzinga.com

BTIG Maintains Buy on ViewRay, Lowers Price Target to $8 - Benzinga - Benzinga

June 17, 2022 | bizjournals.com

Radiation therapy a new frontier for RefleXion, ZAP Surgical Systems - San Francisco Business Times - The Business Journals

June 9, 2022 | benzinga.com

VA Ann Arbor Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy Services - Benzinga - Benzinga

June 9, 2022 | finance.yahoo.com

VA Ann Arbor Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy Services

May 28, 2022 | latimes.com

Newport Coast woman brings her fighter's spirit to cancer battle - Los Angeles Times

May 28, 2022 | nasdaq.com

What Makes ViewRay (VRAY) a New Buy Stock - Nasdaq

May 26, 2022 | finance.yahoo.com

What Makes ViewRay (VRAY) a New Buy Stock

May 15, 2022 | seekingalpha.com

ViewRay: Insider Buying In This $3 Stock - Seeking Alpha

May 14, 2022 | finance.yahoo.com

Scott Drake Is The President of ViewRay, Inc. (NASDAQ:VRAY) And They Just Picked Up 7.5% More Shares - Yahoo Finance

May 14, 2022 | finance.yahoo.com

Scott Drake Is The President of ViewRay, Inc. (NASDAQ:VRAY) And They Just Picked Up 7.5% More Shares

May 11, 2022 | finance.yahoo.com

The past three years for ViewRay (NASDAQ:VRAY) investors has not been profitable

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive VRAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter.

VRAY Company Calendar

Last Earnings: 11/04/2021
Today: 8/17/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Electromedical equipment
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VRAY
CUSIP: N/A
CIK: 1597313
Web: www.viewray.com
Phone: (440) 703-3210
Fax: 800-417-3459
Employees: 267
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $7.00
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +84.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.60)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-110,050,000.00
Net Margins: -131.20%
Pretax Margin: -131.20%
Return on Equity: -75.54%
Return on Assets: -36.55%

Debt

Debt-to-Equity Ratio: 0.47
Current Ratio: 3.04
Quick Ratio: 2.66

Sales & Book Value

Annual Sales: $70.12 million
Price / Sales: 9.78
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.03 per share
Price / Book: 3.68

Miscellaneous

Outstanding Shares: 181,010,000
Free Float: 176,485,000
Market Cap: $686.03 million
Optionable: Optionable
Beta: 1.15

Key Executives

Mr. Scott William Drake (Age 54)
Pres, CEO & Director
Comp: $1.92M
Mr. Zachary William Stassen (Age 43)
Chief Financial Officer
Comp: $637.97k
Mr. Robert S. McCormack (Age 55)
Sr. VP, Gen. Counsel & Corp. Sec.
Comp: $718.2k
Mr. Paul Ziegler Jr. (Age 49)
Chief Commercial Officer
Comp: $978.93k
Dr. James F. Dempsey (Age 51)
Chief Scientific Officer
Ms. Ashley Kluth
Sr. Mang. of Investor Relations
Karen Hackstaff
VP of Marketing
Mr. Robert Michael Fuchs (Age 55)
Chief HR Officer
Dr. Martin Fuss
Chief Medical Officer
Ms. Amanda Sequira (Age 44)
Sr. VP of Clinical, Quality & Regulatory

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VRAY Stock - Frequently Asked Questions

Should I buy or sell ViewRay stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ViewRay in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRAY shares.
View VRAY analyst ratings or view top-rated stocks.
What is ViewRay's stock price forecast for 2022?: 4 Wall Street analysts have issued 12 month target prices for ViewRay's stock. Their VRAY share price forecasts range from $6.00 to $8.00. On average, they anticipate the company's share price to reach $7.00 in the next year. This suggests a possible upside of 84.7% from the stock's current price.
View analysts price targets for VRAY or view top-rated stocks among Wall Street analysts.
How have VRAY shares performed in 2022?: ViewRay's stock was trading at $5.51 at the start of the year. Since then, VRAY stock has decreased by 31.2% and is now trading at $3.79.
View the best growth stocks for 2022 here.
When is ViewRay's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our VRAY earnings forecast.
How were ViewRay's earnings last quarter?: ViewRay, Inc. (NASDAQ:VRAY) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.01. The firm had revenue of $19.18 million for the quarter, compared to analyst estimates of $17.05 million. ViewRay had a negative net margin of 131.20% and a negative trailing twelve-month return on equity of 75.54%. The company's revenue was up 90.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.19) earnings per share.
What guidance has ViewRay issued on next quarter's earnings?: ViewRay updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $90.00 million-$104.00 million, compared to the consensus revenue estimate of $96.82 million.
What is Scott Drake's approval rating as ViewRay's CEO?: 5 employees have rated ViewRay Chief Executive Officer Scott Drake on Glassdoor.com. Scott Drake has an approval rating of 59% among the company's employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ViewRay own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), AbbVie (ABBV), Accuray (ARAY) and Selecta Biosciences (SELB).
When did ViewRay IPO?: (VRAY) raised $52 million in an initial public offering on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers.
What is ViewRay's stock symbol?: ViewRay trades on the NASDAQ under the ticker symbol "VRAY."
Who are ViewRay's major shareholders?: ViewRay's stock is owned by many different retail and institutional investors. Top institutional investors include Artisan Partners Limited Partnership (9.50%), Pura Vida Investments LLC (7.66%), FMR LLC (2.45%), Millennium Management LLC (2.38%), State Street Corp (2.32%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Brian K Roberts, Caley Castelein, Influence Ltd Strong, International Ltd Fosun, James F Dempsey, Scott William Drake, Susan C Schnabel and Zachary William Stassen.
View institutional ownership trends.
How do I buy shares of ViewRay?: Shares of VRAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ViewRay's stock price today?: One share of VRAY stock can currently be purchased for approximately $3.79.
How much money does ViewRay make?: ViewRay (NASDAQ:VRAY) has a market capitalization of $686.03 million and generates $70.12 million in revenue each year. The company earns $-110,050,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.
How many employees does ViewRay have?: The company employs 267 workers across the globe.
How can I contact ViewRay?: ViewRay's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The official website for the company is www.viewray.com. The company can be reached via phone at (440) 703-3210, via email at investors@viewray.com, or via fax at 800-417-3459.

This page (NASDAQ:VRAY) was last updated on 8/17/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

ViewRay - VRAY Stock Forecast, Price & News

ViewRay MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability